133 related articles for article (PubMed ID: 35982394)
1. A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer.
Haji Ghaffari M; Simonian M; Salimi A; Mirzadegan E; Sadeghi N; Nejadmoghaddam MR; Ebrahimnezhad N; Fazli G; Fatemi R; Bayat AA; Mazloomi M; Rabbani H
Breast Cancer; 2022 Nov; 29(6):1121-1132. PubMed ID: 35982394
[TBL] [Abstract][Full Text] [Related]
2. Anchored Fibromodulin as a Novel Target in Chronic Lymphocytic Leukemia: Diagnostic and Therapeutic Implications.
Farahi L; Ghaemimanesh F; Milani S; Razavi SM; Hadavi R; Bayat AA; Salimi A; Akhondi MM; Rabbani H
Iran J Immunol; 2019 Jun; 16(2):127-141. PubMed ID: 31182687
[TBL] [Abstract][Full Text] [Related]
3. The Association of Cell Surface Fibromodulin Expression and Bladder Carcinoma.
Bayat AA; Sadeghi N; Salimi A; Fazli G; Nowroozi MR; Ohadian Moghadam S; Radmanesh A; Tabasi M; Sarrafzadeh AR; Zarei O; Rabbani H
Urol J; 2021 Jul; 19(3):189-195. PubMed ID: 34247360
[TBL] [Abstract][Full Text] [Related]
4. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy.
Si Y; Xu Y; Guan J; Chen K; Kim S; Yang ES; Zhou L; Liu XM
Eng Life Sci; 2021 Jan; 21(1-2):37-44. PubMed ID: 33531889
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer.
Wali VB; Patwardhan GA; Pelekanou V; Karn T; Cao J; Ocana A; Yan Q; Nelson B; Hatzis C; Pusztai L
Sci Rep; 2019 Oct; 9(1):14934. PubMed ID: 31624295
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers.
Si Y; Zhang Y; Guan JS; Ngo HG; Totoro A; Singh AP; Chen K; Xu Y; Yang ES; Zhou L; Liu R; Liu XM
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452008
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal and Polyclonal Antibodies Specific to Human Fibromodulin.
Farahi L; Ghaemimanesh F; Milani S; Razavi SM; Bayat AA; Rabbani H; Akhondi MM
Iran J Biotechnol; 2019 Jan; 17(1):e2277. PubMed ID: 31457049
[TBL] [Abstract][Full Text] [Related]
9. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
Khandelwal S; Boylan M; Spallholz JE; Gollahon L
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
[TBL] [Abstract][Full Text] [Related]
11. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
[TBL] [Abstract][Full Text] [Related]
12. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
Mungra N; Biteghe FAN; Malindi Z; Huysamen AM; Karaan M; Hardcastle NS; Bunjun R; Chetty S; Naran K; Lang D; Richter W; Hunter R; Barth S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12203-12225. PubMed ID: 37432459
[TBL] [Abstract][Full Text] [Related]
13. A new immunochemical strategy for triple-negative breast cancer therapy.
Lin CW; Zheng T; Grande G; Nanna AR; Rader C; Lerner RA
Sci Rep; 2021 Jul; 11(1):14875. PubMed ID: 34290315
[TBL] [Abstract][Full Text] [Related]
14. Chloroform Fraction of Methanolic Extract of Seeds of Annona muricata Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer.
Kariyil BJ; Ayyappan UPT; Gopalakrishnan A; George AJ
Anticancer Agents Med Chem; 2021; 21(10):1250-1265. PubMed ID: 32951586
[TBL] [Abstract][Full Text] [Related]
15. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
16. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
17. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.
Montero JC; Calvo-Jiménez E; Del Carmen S; Abad M; Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2022 Mar; 41(1):106. PubMed ID: 35317825
[TBL] [Abstract][Full Text] [Related]
18. Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer.
Si Y; Zhang Y; Ngo HG; Guan JS; Chen K; Wang Q; Singh AP; Xu Y; Zhou L; Yang ES; Liu XM
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359650
[TBL] [Abstract][Full Text] [Related]
19. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M
Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646
[TBL] [Abstract][Full Text] [Related]
20. α
Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
